Research and Markets: Zentiva IMS Company Profile

Business Wire, April 23, 2009

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/45ebcf/zentiva_ims_compan) has announced the addition of the "Zentiva IMS Company Profile" company profile to their offering.

This Company Profile gives you the authoritative insight into a company at a strategic and local level.

Each individual profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy.

• Critical analyses provided by an in-house expert team
• 90 full in-depth company profiles covering all major pharmaceutical companies worldwide including private companies
• Includes some Generic, Biotechnology and Drug Delivery companies
• Includes sales data on products and therapies
• In depth product and R&D reviews, including clinical trial, lifecycle management, competition and analysts forecasts
• Mergers and acquisitions; licensing agreements
• Forecasts and comments from leading financial analysts
• Companies' conferences, annual reports, press releases
• Comments from stockbrokers/analysts reports used throughout the profile and especially within the Strategy, Financial and Product sections.

Key Topics Covered:

Corporate Structure

Strategy statement

Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:

• M&A
• Regional strategies
• Therapeutic focus
• R&D strategy
• Licensing activities
• Commentary on future prospects, including brokers' overviews
• Interview with a key person (where available), including quotes and opinions
• Forecasting table (top 30 companies only), showing events with major potential impact

Financial Review

Company sales performance as well as analyst's comments and forecasts.

Company Sales Performance:

• Financial review
• Latest results
• Sales by geographical region & leading country
• Sales by country and subsidiary
• Analysis comments

Product Portfolio

Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.

The section shows:

• Summary table of products facing patent expiry.
• Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.

R&D Pipelines

Comprehensive details of the projects that the company has in its R&D pipeline including:

• Research pipeline summary table.
• Introduction to the R&D activities of the company.
• Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.
• Quotes from senior personnel gleaned from conferences may also be included in this section when available.

Key figures

• Sales by business segment.
• Sales by geographical region.

Analyst figures

IMS sales data

• Pharmaceutical sales by geographical region and leading countries.
• Top 5 third level therapeutic classes.
• Leading international products
• Pharmaceutical sales analysis by age

Employee data

Licensing/Co-Marketing Agreements

Displayed in a tabular format to enable you to have "at a glance" review of the licensing activities of the company.

Three sections are available to review licensing activities:

• Marketed products
• R&D pipeline products
• General research collaborations, including combinatorial chemistry, proprietary technologies etc.

Major Events

Summary of the major events that have affected the company. This includes recent and historical events.

Two sections

• Mergers and Acquisitions
• Other major events

Events are organised in chronological order.

Subsidiaries listing

Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.

For more information visit http://www.researchandmarkets.com/research/45ebcf/zentiva_ims_compan.

Source: IMS Health